BusinessCytokinetics Announces Start of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv MecarbilBy Nasdaq OMXDec 1, 2016, 12:30 PM UTC
BusinessThe Lancet Publishes Results From COSMIC-HF Trial Showing Omecamtiv Mecarbil Significantly Improved Cardiac Function in Patients With Chronic Heart FailureBy Nasdaq OMXNov 30, 2016, 11:30 PM UTC
BusinessCytokinetics to Participate in Upcoming Investor ConferencesBy Nasdaq OMXNov 22, 2016, 9:00 PM UTC
BusinessCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the AHA Annual Scientific MeetingBy Nasdaq OMXNov 14, 2016, 9:00 PM UTC
BusinessCytokinetics Announces New Results From COSMIC-HF to be Presented at the American Heart Association Scientific Sessions 2016By Nasdaq OMXNov 7, 2016, 9:00 PM UTC
BusinessCytokinetics Announces Publication Relating to Novel Smooth Muscle Myosin InhibitorBy Nasdaq OMXNov 7, 2016, 12:30 PM UTC
BusinessCytokinetics, Inc. Reports Third Quarter 2016 Financial ResultsBy Nasdaq OMXOct 27, 2016, 8:01 PM UTC
BusinessCytokinetics Announces First Patient Enrolled in VIGOR-ALS, an Open-Label Extension Clinical Trial of TirasemtivBy Nasdaq OMXOct 18, 2016, 11:30 AM UTC
